Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Cholecalciferol within osteoporosis/vitamin D deficiency gave ROR 7.93 (5.96 to 10.6), consistent with its co-prescription with antiresorptives within that indication rather than with an independent effect (it also loses four-criterion status when antiresorptive reports are removed, Supplementary Table S5).

Source: Indication-restricted analysis. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Glucocorticoid-centered drug spectrum of non-jaw osteonecrosis, a FAERS pharmacovigilance study with independent validation in Canada Vigilance and JADER

Study design awaiting verification · Frontiers in Pharmacology · 2026

Original publication title

Glucocorticoid-centered drug spectrum of non-jaw osteonecrosis, a FAERS pharmacovigilance study with independent validation in Canada Vigilance and JADER

Lisheng Qi; Yu Qiu; Xiaobin Wang; Tao Zhang; Huacai Jiang

Copyright © 2026 Qi, Qiu, Wang, Zhang and Jiang.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The reproducible spectrum is glucocorticoid-centered, with the asparaginase class the best-supported residual and three drugs unresolved. Jaw misclassification, reporting context, and indication explain much of the apparent spectrum. Spontaneous reports cannot establish causation; these adjudications require cohort confirmation. The JPI and cross-jurisdiction comparisons may inform analyses of other misclassification-prone endpoints.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To distinguish jaw misclassification and litigation-related reporting from non-jaw osteonecrosis signals and define their reproducible spectrum.

Source: Objective

Abstract: What methods does the paper describe?

We analyzed 20,690,895 deduplicated Food and Drug Administration Adverse Event Reporting System (FAERS) reports (2004Q1: 2026Q2), using report-level adjudication and four disproportionality criteria. A descriptive jaw-propensity index (JPI) measured the share of each drug’s osteonecrosis reports coded as “jaw.” Reporter restrictions and comparisons with Canada Vigilance and the Japanese Adverse Drug Event Report (JADER) database examined reporting bias. These external databases recorded less solicitation. Additional analyses included glucocorticoid stratification, empirical null calibration with unmasking, indication restriction of every surviving non-glucocorticoid drug, time-to-onset modeling, and machine learning.

Estimates are reported with 95% confidence intervals.

Source: Methods

Abstract: Results

Of 47 signals, 27 passed jaw exclusion (JPI < 0.50) and reporter restriction; the final core was unchanged across thresholds of 0.30 to 0.70. Tenofovir disoproxil’s reporting odds ratio (ROR) fell from 157.9 (153.4 to 162.6) to 6.33 (5.38 to 7.45) among health professionals; 84.5% of cases were lawyer-sourced. Canada Vigilance (6.24, 2.00 to 19.4) and JADER (10.5, 6.60 to 16.8) were consistent with a litigation-inflated FAERS estimate. Glucocorticoids were replicated in both databases (class RORs 10.3, 54.4). Drug JPI rankings were concordant (r = 0.985, 0.960). All 34 negative controls had ROR < 1 (median 0.16); unmasking rescaled other estimates approximately 2.35-fold.

Within-indication analyses detected no residual excess for mycophenolate (0.89) or voxelotor (0.97). Asparaginase combined a within-leukemia residual signal (7.14, 5.10 to 10.0) with mechanistic evidence and JADER replication (75.7).

Source: Results

Abstract: Conclusion

The reproducible spectrum is glucocorticoid-centered, with the asparaginase class the best-supported residual and three drugs unresolved. Jaw misclassification, reporting context, and indication explain much of the apparent spectrum. Spontaneous reports cannot establish causation; these adjudications require cohort confirmation. The JPI and cross-jurisdiction comparisons may inform analyses of other misclassification-prone endpoints.

Source: Conclusion
Authors’ abstract

Objective

To distinguish jaw misclassification and litigation-related reporting from non-jaw osteonecrosis signals and define their reproducible spectrum.

Methods

We analyzed 20,690,895 deduplicated Food and Drug Administration Adverse Event Reporting System (FAERS) reports (2004Q1: 2026Q2), using report-level adjudication and four disproportionality criteria. A descriptive jaw-propensity index (JPI) measured the share of each drug’s osteonecrosis reports coded as “jaw.” Reporter restrictions and comparisons with Canada Vigilance and the Japanese Adverse Drug Event Report (JADER) database examined reporting bias. These external databases recorded less solicitation. Additional analyses included glucocorticoid stratification, empirical null calibration with unmasking, indication restriction of every surviving non-glucocorticoid drug, time-to-onset modeling, and machine learning.

Estimates are reported with 95% confidence intervals.

Results

Of 47 signals, 27 passed jaw exclusion (JPI < 0.50) and reporter restriction; the final core was unchanged across thresholds of 0.30 to 0.70. Tenofovir disoproxil’s reporting odds ratio (ROR) fell from 157.9 (153.4 to 162.6) to 6.33 (5.38 to 7.45) among health professionals; 84.5% of cases were lawyer-sourced. Canada Vigilance (6.24, 2.00 to 19.4) and JADER (10.5, 6.60 to 16.8) were consistent with a litigation-inflated FAERS estimate. Glucocorticoids were replicated in both databases (class RORs 10.3, 54.4). Drug JPI rankings were concordant (r = 0.985, 0.960). All 34 negative controls had ROR < 1 (median 0.16); unmasking rescaled other estimates approximately 2.35-fold.

Within-indication analyses detected no residual excess for mycophenolate (0.89) or voxelotor (0.97). Asparaginase combined a within-leukemia residual signal (7.14, 5.10 to 10.0) with mechanistic evidence and JADER replication (75.7).

Conclusion

The reproducible spectrum is glucocorticoid-centered, with the asparaginase class the best-supported residual and three drugs unresolved. Jaw misclassification, reporting context, and indication explain much of the apparent spectrum. Spontaneous reports cannot establish causation; these adjudications require cohort confirmation. The JPI and cross-jurisdiction comparisons may inform analyses of other misclassification-prone endpoints.

Publication and source details

Original title: Glucocorticoid-centered drug spectrum of non-jaw osteonecrosis, a FAERS pharmacovigilance study with independent validation in Canada Vigilance and JADER

Lisheng Qi; Yu Qiu; Xiaobin Wang; Tao Zhang; Huacai Jiang

Frontiers in Pharmacology · 2026

* Correspondence: Tao Zhang, 130225@swmu.edu.cn; Huacai Jiang, 15282464749@163.com
†

These authors have contributed equally to this work

Copyright © 2026 Qi, Qiu, Wang, Zhang and Jiang.2026Qi, Qiu, Wang, Zhang and Jianghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:19:23.051839+00:00

DOI: 10.3389/fphar.2026.1977191 · PMC13731382